4.2 Review

An update on the comorbidity of ADHD and ASD: a focus on clinical management

Journal

EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 16, Issue 3, Pages 279-293

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1586/14737175.2016.1146591

Keywords

developmental delay; neurodevelopmental disorder; ADHD; autism spectrum disorder; children; adolescent; comorbidity; ASD

Funding

  1. Pfizer
  2. Ironshore
  3. Shire
  4. Akili Interactive Labs
  5. CogCubed
  6. Alcobra
  7. VAYA Pharma
  8. Neurovance
  9. Impax
  10. NeuroLifeSciences
  11. Otsuka
  12. McNeil
  13. Janssen
  14. Novartis
  15. Eli Lilly

Ask authors/readers for more resources

Attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) commonly co-occur. With the DSM-5, clinicians are permitted to make an ASD diagnosis in the context of ADHD. In earlier versions of the DSM, this was not acceptable. Both ASD and ADHD are reported to have had substantial increases in prevalence within the past 10 years. As a function of both the increased prevalence of both disorders as well as the ability to make an ASD diagnosis in ADHD, there has been a significant amount of research focusing on the comorbidity between ADHD and ASD in the past few years. Here, we provide an update on the biological, cognitive and behavioral overlap/distinctiveness between the two neurodevelopmental disorders with a focus on data published in the last four years. Treatment strategies for the comorbid condition as well as future areas of research and clinical need are discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available